Obese men at high risk for prostate cancer even after benign biopsy

April 23, 2013, Columbia University's Mailman School of Public Health

Obese men were more likely to have precancerous lesions detected in their benign prostate biopsies compared with non-obese men, and were at a greater risk for subsequently developing prostate cancer, according to researchers at Columbia University's Mailman School of Public Health. The findings will be published online in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

"Our study is focused on a large group of men who have had a prostate that is benign but are still at a very high risk for prostate cancer," said Andrew Rundle, DrPH, associate professor of Epidemiology and the first author of the paper. "Studies conducted in the past have attempted to determine if there are subpopulations of men diagnosed with benign conditions that may be at a greater risk for developing prostate cancer. Here we were able to show that obesity is associated with a significantly higher risk of prostate cancer after an initial benign biopsy, particularly in the first few years after a biopsy. This was also one of the first studies to assess the association between obesity and precancerous abnormalities in the benign biopsy tissue specimens."

Dr. Rundle and his colleagues investigated the association between obesity and future prostate cancer incidence within a cohort of 6,692 men at the Henry Ford Health System who were followed for 14 years after a biopsy or transurethral resection of the prostate with benign findings. The investigation was part of a larger study for prostate cancer funded through a research grant by the National Institutes of Health to the Henry Ford Health System.

The researchers conducted a case-control study among 494 of these patients and 494 matched controls; they found precancerous abnormalities in 11% of the patients' benign specimens. These abnormalities were significantly associated with obesity at the time of the procedure, according to Dr. Rundle.

After accounting for several variables, including family history of prostate cancer, prostate-specific antigen (PSA) levels during the initial procedure, and the number of PSA tests and digital rectal exams during follow-up, the researchers found that obesity at the time of the initial procedure was associated with a 57% increased incidence of prostate cancer during follow-up.

Dr. Rundle noted, however, that this association was only apparent for tumors occurring earlier in the follow-up period. "We don't absolutely know what the true biology is," he said. "In some ways, this reflects the association between the body size and larger prostate size, which is thought to reduce the sensitivity of the needle biopsy. It is possible that the tumors missed by initial biopsy grew and were detected in a follow-up biopsy."

The association observed between body size and prostate cancer risk is greater than that seen in prior studies, according to Dr. Rundle. He attributed the discrepancy to differences between the cohorts studied; the current study was composed only of men at high risk for . In addition, since these high-risk were members of the comprehensive Henry Ford Medical System, they underwent increased medical surveillance, which included repeated biopsy and regular PSA screening.

"We need some guidance on when or for whom a full follow-up is required," said Dr. Rundle. "Obesity should be considered a factor for more intensive follow-up after a benign prostate biopsy."

Explore further: PSA test valuable in predicting biopsy need, low-risk prostate cancer

Related Stories

PSA test valuable in predicting biopsy need, low-risk prostate cancer

October 21, 2011
The prostate-specific antigen test, commonly known as the PSA test, is valuable in predicting which men should have biopsies and which are likely to be diagnosed with low-risk prostate cancer, a Mayo Clinic study has found. ...

Genetic testing may be used to identify BPH patients with increased risk of prostate cancer

March 19, 2013
Patients with benign prostatic hyperplasia (BPH) carrying prostate cancer (PCa) a risk alleles are a potential target population for PCa screening and follow-up, according to a study, which was presented yesterday at the ...

When rising PSA means prostate cancer is in patient's future

May 18, 2011
A man's rising PSA (prostate-specific antigen) level over several years – which had been seen as a possible warning sign of prostate cancer – has recently come under fire as a screening test because it sometimes ...

New imaging agent has an appetite for dangerous prostate tumors

December 8, 2011
Non-invasive imaging detects prostate cancer earlier than ever before, but can't accurately distinguish between malignant and benign disease. According to Lawson Health Research Institute's Drs. John Lewis and Len Luyt, a ...

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.